Omeros (OMER) – Research Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Omeros (NASDAQ: OMER) recently:

• 4/26/2026 – Omeros was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/21/2026 – Omeros had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/21/2026 – Omeros had its “buy” rating reaffirmed by D. Boral Capital. They now have a $36.00 price target on the stock.
• 4/18/2026 – Omeros was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/4/2026 – Omeros was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/2/2026 – Omeros was upgraded by Zacks Research from “hold” to “strong-buy”.

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.